medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 2

<< Back Next >>

Ann Hepatol 2018; 17 (2)

Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse

Sookoian S, Pirola CJ

Language: English
References: 28
Page: 182-186
PDF size: 1889.86 Kb.


ABSTRACT

Phenotypic modulation of NAFLD-severity by molecules derived from white (adipokines) and brown (batokines) adipose tissue may be important in inducing or protecting against the progression of the disease. Adipose tissue-derived factors can promote the progression of NAFLD towards severe histological stages (NASH-fibrosis and NASHcirrhosis). This effect can be modulated by the release of adipokines or batokines that directly trigger an inflammatory response in the liver tissue or indirectly modulate related phenotypes, such as insulin resistance. Metabolically dysfunctional adipose tissue, which is often infiltrated by macrophages and crown-like histological structures, may also show impaired production of anti-inflammatory cytokines, which may favor NAFLD progression into aggressive phenotypes by preventing its protective effects on the liver tissue.


REFERENCES

  1. Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015; 17: 15080.

  2. Sookoian S, Gianotti TF, Rosselli MS, Burgueno AL, Castano GO, Pirola CJ. Liver transcriptional profile of atherosclerosis- related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011; 218: 378-85.

  3. Sookoian S, Castano GO, Burgueno AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010; 209: 585-91.

  4. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-7.

  5. Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int J Mol Sci 2017 29; 18(8).

  6. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65: 1062- 79.

  7. Sookoian S, Rosselli MS, Gemma C, Burgueno AL, Fernandez GT, Castano GO, Pirola CJ. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 2010; 52: 1992-2000.

  8. Pirola CJ, Scian R, Gianotti TF, Dopazo H, Rohr C, Martino JS, Castano GO, et al. Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins. Medicine (Baltimore) 2015; 94: e1480.

  9. Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol 2017; 23: 1-12.

  10. Guo L, Zhang P, Chen Z, Xia H, Li S, Zhang Y, Kobberup S, et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J Clin Invest 2017 November 6 [Epub ahead of print].

  11. Sookoian S, Castano GO, Scian R, San MJ, Pirola CJ. Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH). Sci Rep 2016; 3:22528.

  12. Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Gianotti TF, Martino JS, et al. Mitochondrial genome architecture in non-alcoholic fatty liver disease. J Pathol 2016; 240: 437- 49.

  13. Sookoian S, Pirola CJ. The NASH Metabotype: Imbalance of Circulating Amino Acids and Transamination Reactions Reflect Impaired Mitochondrial Function. Hepatology 2017 [Epub ahead of print]

  14. Sookoian S, Castano GO, Scian R, Fernandez GT, Dopazo H, Rohr C, Gaj G, et al. Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level. Am J Clin Nutr 2016; 103: 422-34.

  15. Du K, Hyun J, Premont RT, Choi SS, Michelotti GA, Swiderska- Syn M, Dalton GD, et al. Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Hepatic Stellate Cell Activation. Gastroenterology 2018 [Epub ahead of print].

  16. Chen Y, Choi SS, Michelotti GA, Chan IS, Swiderska-Syn M, Karaca GF, Xie G, et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism. Gastroenterology 2012; 143: 1319-29.

  17. Verdelho MM, Diehl AM. Role of Hedgehog Signaling Pathway in NASH. Int J Mol Sci 2016; 17(6).

  18. Cotter DG, Ercal B, Huang X, Leid JM, d’Avignon DA, Graham MJ, Dietzen DJ, et al. Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J Clin Invest 2014; 124: 5175-90.

  19. Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999; 18: 2681-9.

  20. Wang GX, Zhao XY, Meng ZX, Kern M, Dietrich A, Chen Z, Cozacov Z, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med 2014; 20(12): 1436-43.

  21. Kang YE, Kim JM, Choung S, Joung KH, Lee JH, Kim HJ, Ku BJ. Comparison of serum Neuregulin 4 (Nrg4) levels in adults with newly diagnosed type 2 diabetes mellitus and controls without diabetes. Diabetes Res Clin Pract 2016; 117: 1-3.

  22. Yan PJ, Xu Y, Wan Q, Feng J, Li H, Gao CL, Yang J, et al. Decreased plasma neuregulin 4 concentration is associated with increased high-sensitivity C-reactive protein in newly diagnosed type 2 diabetes mellitus patients: a cross-sectional study. Acta Diabetol 2017; 54: 1091-9.

  23. Kralisch S, Hoffmann A, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M, Ebert T. The brown-fat-secreted adipokine neuregulin 4 is decreased in gestational diabetes mellitus. Diabetes Metab 2017 [Epub ahead of print].

  24. Kurek EM, Yayla AC, Sahin EG, Altun ET, Pekin O, Cevik O. Clinical significance of neuregulin 4 (NRG4) in gestational diabetes mellitus. Gynecol Endocrinol 2017; 28: 1-4.

  25. Cai C, Lin M, Xu Y, Li X, Yang S, Zhang H. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study. BMC Med 2016; 14: 165.

  26. Dai YN, Zhu JZ, Fang ZY, Zhao DJ, Wan XY, Zhu HT, Yu CH, et al. A case-control study: Association between serum neuregulin 4 level and non-alcoholic fatty liver disease. Metabolism 2015; 64: 1667-73.

  27. South JC, Blackburn E, Brown IR, Gullick WJ. The neuregulin system of ligands and their receptors in rat islets of langerhans. Endocrinology 2013; 154: 2385-92.

  28. Saleheen D, Natarajan P, Armean IM, Zhao W, Rasheed A, Khetarpal SA, Won HH, et al. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature 2017; 544: 235-9.




2020     |     www.medigraphic.com